Recent Updates
Recently added Catalysts

AHB-137

Phase 2

Hepatitis B, Chronic | Small molecule | Infectious Disease |cbdMD, Inc.|Last Updated: Aug 26, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLEDDMCBiomarker
Total Trials1
Total Enrollment70

FDA Designations

No designations recorded

Clinical trial landscape

AHB-137 · 1 trial · 1 indication

Phase 2 1
NCT07654283Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe RegionsHepatitis B, Chronic
RECRUITING70 Analytics
PHASE2RECRUITING
Study of AHB-137 in Chronic Hepatitis B (CHB) Participants in North America and Europe Regions
Hepatitis B, Chronic
NCT0765428370
Unlock trial analytics

Study Endpoints

Primary Endpoints

Proportion of participants with persistent HBsAg < limit of detection (LOD) and HBV DNA < lower limit of quantification (LLOQ)
24 Weeks post AHB-137 treatment (Week 48)

Secondary Endpoints

Proportion of participants with HBsAg < LOD and HBV DNA < LLOQ
Off-treatment follow-up (Week 48 to 72)
Proportion of participants with HBsAg < LOD
Week 72
Proportion of participants with HBV DNA < LLOQ
From baseline through Week 72
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Arm A: Dose Regimen AEXPERIMENTALParticipants receive AHB-137 according to dosing regimen A.
Arm B: Dose Regimen BEXPERIMENTALParticipants receive AHB-137 according to dosing regimen B.

Interventions

NameTypeDescription
AHB-137DRUGSubcutaneous injection
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites10

Inclusion Criteria: Participants are eligible to be included in the study only if all of the following criteria apply: 1. Adults ≥18 years of age and up to 65 years of age (inclusive) at Screening who are able to provide informed consent, comply with study procedures, and agree to discontinue nucl...

Countries:United StatesCanadaFranceItalySpainUnited Kingdom
Unlock Eligibility Criteria